CAMP4 Therapeutics Corporation Operating Expenses
CAMP4 Therapeutics Corporation (CAMP) reported Operating Expenses of $15.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- CAMP4 Therapeutics Corporation operating expenses for the quarter ending 2026-06-30 was $15.16M, a 4.36% increase year-over-year.
- CAMP4 Therapeutics Corporation operating expenses for the quarter ending 2026-03-31 was $14.37M, a 2.92% increase year-over-year.
- CAMP4 Therapeutics Corporation operating expenses for the quarter ending 2025-12-31 was $13.12M, a 10.64% decline year-over-year.
- CAMP4 Therapeutics Corporation operating expenses for the quarter ending 2025-09-30 was $14.45M, a 6.88% increase year-over-year.
- CAMP4 Therapeutics Corporation operating expenses for fiscal 2025 was $56.05M, a 4.30% increase from fiscal 2024.
- CAMP4 Therapeutics Corporation operating expenses for fiscal 2024 was $53.74M, a 2.89% increase from fiscal 2023.
- CAMP4 Therapeutics Corporation operating expenses for fiscal 2023 was $52.23M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.16M 10-Q · filed 2026-08-13 | $29.52M 10-Q · filed 2026-08-13 | $42.65M derived: sum of 3 quarters · filed 2026-08-13 | $57.09M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $14.37M 10-Q · filed 2026-05-07 | $27.49M derived: sum of 2 quarters · filed 2026-05-07 | $41.94M derived: sum of 3 quarters · filed 2026-05-07 | $56.46M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $13.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $27.57M derived: sum of 2 quarters · filed 2026-03-05 | $42.09M derived: sum of 3 quarters · filed 2026-08-13 | $56.05M 10-K · filed 2026-03-05 |
| 2025-09-30 | $14.45M 10-Q · filed 2025-11-06 | $28.97M derived: sum of 2 quarters · filed 2026-08-13 | $42.93M 10-Q · filed 2025-11-06 | $57.62M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $14.53M 10-Q · filed 2026-08-13 | $28.48M 10-Q · filed 2026-08-13 | $43.17M derived: sum of 3 quarters · filed 2026-08-13 | $56.69M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $13.96M 10-Q · filed 2026-05-07 | $28.64M derived: sum of 2 quarters · filed 2026-05-07 | $42.16M derived: sum of 3 quarters · filed 2026-05-07 | $54.82M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $14.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $28.20M derived: sum of 2 quarters · filed 2026-03-05 | $40.86M derived: sum of 3 quarters · filed 2026-03-05 | $53.74M 10-K · filed 2026-03-05 |
| 2024-09-30 | $13.52M 10-Q · filed 2025-11-06 | $26.18M derived: sum of 2 quarters · filed 2025-11-06 | $39.05M 10-Q · filed 2025-11-06 | $52.53M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $12.66M 10-Q · filed 2025-08-14 | $25.54M 10-Q · filed 2025-08-14 | $39.01M derived: sum of 3 quarters · filed 2025-08-14 | $51.70M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $12.88M 10-Q · filed 2025-05-13 | $26.35M derived: sum of 2 quarters · filed 2025-05-13 | $39.04M derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | $13.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $26.16M derived: sum of 2 quarters · filed 2025-03-27 | $52.23M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $12.69M 10-Q · filed 2024-11-21 | $38.75M 10-Q · filed 2024-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |